Drug Trial Radar · NCT05633992
Safety and Immunogenicity of V116 in Vaccine-naïve Japanese Older Adults (V116-009, STRIDE-9)
Last checked: Nov 19, 2026Latest source record: Oct 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
450
Actual
Start
Jan 10, 2023
Primary completion
May 24, 2023
Study completion May 24, 2023
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Dec 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a phase 3, randomized, double-blind, active comparator-controlled study of the safety, tolerability, and immunogenicity of V116 in pneumococcal vaccine-naïve Japanese adults 65 years of age and older. The polyvalent (23-valent) pneumococcal vaccine, PPSV23, is the active comparator. In addition to studying safety/tolerability, it is hypothesized that, at 30 days postvaccination, the immunogenicity of V116 is noninferior to PPSV23 for the 12 common serotypes in V116 and PPSV23 and the cross-reactive serotype 15B in V116, and that the immunogenicity of V116 is superior to PPSV23 for the unique serotype 15C in V116. It is also hypothesized that V116 is superior to PPSV23 in the percentage of participants with ≥4-fold rise from baseline in the 8 unique V116 serotypes (except for 15C), as measured by serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs).
Conditions
- Pneumococcal Disease
Interventions
V116Biological
Sterile 0.5 mL solution in prefilled syringe containing 4 μg of each pneumococcal polysaccharide (PnPs) antigen 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B.
PPSV23Biological
Sterile 0.5 mL solution in prefilled syringe containing 25 μg of each PnPs antigen 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Solicited Injection-site Adverse Events (AEs)Time frame: Up to 5 days postvaccination
- Percentage of Participants With Solicited Systemic AEsTime frame: Up to 5 days postvaccination
- Percentage of Participants With Vaccine-related Serious AEs (SAEs)Time frame: Up to 30 days postvaccination
- Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs)Time frame: Day 30 postvaccination
- Percentage of Participants With ≥4-fold Rise From Baseline in Serotype-specific OPAs (Unique to V116)Time frame: Baseline (Day 1) and Day 30 postvaccination
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
PS Clinic ( Site 1002)
Fukuoka, Japan
Nishikumamoto Hospital ( Site 1007)
Kumamoto, Japan
Medical Corporation Heishinkai OPHAC Hospital ( Site 1008)
Osaka, Osaka, Japan
Medical Corporation Heishinkai OCROM Clinic ( Site 1003)
Suita-shi, Osaka, Japan
P-One Clinic ( Site 1001)
Hachiōji, Tokyo, Japan
Heishinkai Medical Group ToCROM Clinic ( Site 1004)
Shinjuku-ku, Tokyo, Japan
Medical Corporation Shinanokai Shinanozaka Clinic ( Site 1006)
Shinjuku-ku, Tokyo, Japan
Medical Corporation Houeikai Sekino Clinical Pharmacology Clinic ( Site 1005)
Toshima City, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.